Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

216. Brooks Automation Acquires Life Sciences Consumables Provider 4titude,

Brooks Automation Acquires Life Sciences Consumables Provider 4titude, Ltd. and Secures $200 Million Term Loan 05/10/2017Brooks Automation, Inc. (Nasdaq:BRKS) announced today that it has acquired 4titude, Ltd., a manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications. Based in Surrey, England, 4titude sells its products into more than 50 countries worldwide. The total purchase price of the acquisition was approxima


217. Laboratory Informatics

Laboratory Informatics A term used to describe a wide range of products designed to aid the researcher, it includes electronic lab notebooks (e-LN), Laboratory Information Systems as well as tools used for data-mining, acquisition and data processing. The area continues to grow, and at the SBC we recognised that everyone had their own specific requirements. To help you get started we have shortlisted a few providers in the area of compound and array design, registration, physio-chemical pro


218. Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders Boehringer Ingelheim and Autifony Therapeutics Limited (“Autifony”) today announced that they have signed an agreement about certain aspects of Autifony’s voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform. Included in the agreement is the l


219. Freeline

 Freeline TherapeuticsFreeline’s mission is to become a leading biopharmaceutical company founded on the successful development and commercialisation of liver directed gene therapies for bleeding disorders and other severe diseases.These therapies are based on our next-generation proprietary AAV vector platform, with our lead programme being a gene therapy to treat haemophilia B. This gene therapy treatment, pioneered by Professor Amit Nathwani, Professor of Haematology at UCL and CSO



Page 44 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019